Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

New experimental drug can help treat peripheral neuropathy in cancer patients

Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment.

11 Apr 2011

Biological Psychiatry publishes Omeros' PPAR-gamma addiction program

Omeros Corporation today announced that research on the PPAR-gamma agonists it is developing in its Addiction franchise has been published in the April 1, 2011 issue of the Journal of Biological Psychiatry.

7 Apr 2011

Higher prescribed doses associated with increased risk of opioid overdose death

In an analysis of opioid prescription patterns and deaths, receiving higher prescribed doses is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk, according to a study in the April 6 issue of JAMA.

6 Apr 2011

Patients prescribed high doses of pain medications at higher risk of overdose: Study

According to a study published in the April 6 issue of the Journal of the American Medical Association JAMA, receiving higher prescribed doses of opioid prescriptions is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk.

5 Apr 2011

New findings may make morphine a safer, more effective drug for chronic pain control

An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.

25 Mar 2011

High sugar, high fat diets during pregnancy may cause infants to become junk food junkies

A new research report published online in The FASEB Journal suggests that pregnant mothers who eat high sugar and high fat diets have babies who are likely to become junk food junkies themselves. According to the report, which used rats, this happens because the high fat and high sugar diet leads to changes in the fetal brain's reward pathway, altering food preferences.

24 Mar 2011

New research: Methadone can affect brain and impair intellectual functions

Methadone has been used to treat heroin addicts for nearly 50 years. Yet we have surprisingly incomplete knowledge about possible harmful effects from prolonged use. New research from the Norwegian Institute of Public Health shows that methadone affects the brain and impairs the attention of experimental animals.

24 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Smoking during pregnancy increases risk of children becoming smokers too

New research has revealed that prenatal exposure to nicotine increases the vulnerability to nicotine self-administration in adolescent mice. The results support the hypothesis that adolescents with prenatal nicotine exposure are more likely to start smoking earlier than their peers and that they are also more susceptible to the addictive effects of nicotine, especially as a result of stress and peer pressure.

21 Mar 2011

Non-adherence to chronic opioid therapy increases healthcare costs and hospital days

Patients undergoing opioid therapy for chronic pain who may not be following their prescription regimen have significantly higher overall healthcare costs, Ameritox Ltd. announced recently. The study was published in The American Journal of Managed Care.

18 Mar 2011

Naltrexone may be effective in women with specific genetic variation

Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone, one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation.

17 Mar 2011

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC).

16 Mar 2011

Research links frequent prescribing to opioid-related deaths

Some physicians are prescribing opioids such as OxyContin 55 times as often as others, according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). The study found most opioid-related deaths occur among patients treated by physicians who frequently prescribe opioids, suggesting doctors who prescribe a lot of opioids may not be doing so safely.

15 Mar 2011

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.

10 Mar 2011

FDA's action impacts Elite pharma drugs

Elite Pharmaceuticals, Inc. advises that the US Food and Drug Administration announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market.

7 Mar 2011

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs — despite the potential for abuse, addiction and overdose, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University.

4 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

QRxPharma granted FDA pre-NDA meeting, further phase II data released

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.

20 Feb 2011

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.

18 Feb 2011